AndreaBozzo/ceres-open-data-index huggingface dataset:
From Waterfall to Agile: Managing Cultural Change and Impacts Across Stakeholder Groups

As Agile continues to grow in popularity, more organizations are experiencing the frustration associated with attempts to move from traditional waterfall to Agile practices. Agile requires more than simply knowing how to do Scrum; it involves organizational and cultural change. Leaders of successful Agile projects recognize and manage this cultural change and the impacts it has on all stakeholders.

Our webinar, "From Waterfall to Agile: Managing Cultural Change and Impacts Across Stakeholder Groups," presents the experience of several states in implementing the Agile methodology and the various impacts on stakeholder groups. Presenters include Kevin Burt, Assistant Director for the Eligibility Services Division, Utah Department of Workforce Services; Wade Owen, Technical Director, Utah Child Welfare Management System (SAFE); and Tom Kine, Minnesota Statewide Automated Child Welfare Information Systems Manager and SQL Server Integration Services (SSIS) Application and Development Supervisor.

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E399546-T1: [Translated] CYCLOALKYL-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROIDDEHYDROGENASE 1

The present invention provides compounds of formula I that are useful as potent and selective inhibitors of 11-beta hydroxysteroid dehydrogenase 1. The present invention further provides a pharmaceutical composition which comprises a compound of Formula I, or a pharmaceutical salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. In addition, the present invention compositions containing these compounds for the treatment of metabolic syndrome, diabetes, hyperglycemia obesity, hypertension, hyperlipidemia, other symptoms associated with hyperglycemia, and related disorders. Formula I wherein G<SUP>1 </SUP>is methylene or ethylene; L is -(C<SUB>1</SUB>-C<SUB>4</SUB>)alkylene-, -S-, -CH(OH)-, or -O-; R<SUP>0 </SUP>is Formula II or Formula III and the other substituents are as defined in the claims.
Patent AT-E400669-T1: [Translated] METHOD FOR PRODUCING METAL COMPOSITE MATERIAL

The present invention provides a method of producing a metal composite material by dissolving at least one inorganic metal salt of Mo and/or W optionally together with one or more organic iron group metal salts in water and possibly at least another polar solvent, complex binding the metals with at least one complex former comprising functional groups in the form of OH or NR3, (R=H or alkyl). The amount of said salt of Mo and/or W in the solution should be no more than 4 x 10<-3> x (wt% H2O)<2> g/100 ml solution and not less than 10 wt-% water. The method further includes adding hard constituent powder to the solution, evaporating the solvent and heat treating the remaining powder in an inert and/or reducing atmosphere. As a result coated hard constituent powder is obtained which after addition of pressing agent and optionally with other coated hard constituent powders and/or carbon to obtain the desired composition can be compacted and sintered according to standard practice.
Climate Shield Bull Trout (0% Brook Trout), 2040 (Feature Layer)

This feature class represents the mid-century (2030-2059) scenario for bull trout, derived from the Climate Shield fish distribution models. These models provide stream-specific probabilistic predictions about the occurrence of juvenile bull trout and cutthroat trout in association with three different scenarios for climate change and brook trout invasions. These datasets indicate all potential cold-water habitats less than 11 degrees Celsius. The attribute fields BT_0BRK - BT_100BRK indicate the probabilities of bull trout occurrence within a cold-water habitat based on the prevalence of brook trout at 0%, 25%, 50%, 75%, or 100% of the sites within a habitat. The probabilities were predicted using the Climate Shield native trout models developed from known species occurrence in greater than 500 cold-water streams. The stream centerlines were based on the National Hydrography Dataset (NHD) but were modified for purposes of modeling and cross-walking to other datasets.
Compound 526270: 1,3,4,9-Tetrabromo-dibenzofuran

Chemical compound data from PubChem database. IUPAC Name: 1,3,4,9-tetrabromodibenzofuran. Molecular Formula: C12H4Br4O. Molecular Weight: 483.77. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525719: p-Methylbenzylidene-(4-ethoxyphenyl)-amine

Chemical compound data from PubChem database. IUPAC Name: N-(4-ethoxyphenyl)-1-(4-methylphenyl)methanimine. Molecular Formula: C16H17NO. Molecular Weight: 239.31. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Provider Network Data: 2025 Quarter 1

This Provider Network Data file contains information on individual providers and institutional providers (i.e., hospitals, labs, home care agencies) participating in health plan networks from January through March 2025. Plan network data is collected from Medicaid, Commercial, and Exchange plans on a quarterly basis by the Department of Health, including Managed Care Organizations (MCOs), Preferred Provider Organizations (PPOs) and Exclusive Provider Organizations (EPOs) plans.

For more information, please visit: <a href=https://pndslookup.health.ny.gov>https://pndslookup.health.ny.gov</a>
2020-2021 Nationwide Blood Donor Seroprevalence Survey Combined Infection- and Vaccination-Induced Seroprevalence Estimates

CDC is collaborating with the National Institutes of Health (NIH), the Food and Drug Administration (FDA), Vitalant Research Institute (VRI), Westat Inc., and numerous blood collection organizations across the United States to conduct a nationwide COVID-19 seroprevalence survey of blood donors. This is the largest nationwide COVID-19 seroprevalence survey to date. De-identified blood samples are tested for antibodies to SARS-CoV-2 to better understand the percentage of people in the United States who have antibodies against SARS-CoV-2 (the virus that causes COVID-19) and to track how this percentage changes over time. Both SARS-CoV-2 infection and COVID-19 vaccines currently used in the United States result in production of anti-spike (anti-S) antibodies but only infection results in production of anti-nucleocapsid (anti-N) antibodies. Combined seroprevalence estimates the proportion of the population with evidence of previous SARS-CoV-2 infection, COVID-19 vaccination, or both. It estimates the proportion of the population with some presumed protection against infection with the virus that causes COVID-19. The term “combined seroprevalence” refers to the combined infection- and vaccination-induced SARS-CoV-2 seroprevalences. This is the population that has  anti-S antibodies, regardless of the presence of anti-N antibodies.

This link connects to a webpage that displays the data from the Nationwide Blood Donor Seroprevalence Survey. It offers an interactive visualization available at https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence

Additional information is available at: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/blood-bank-serosurvey.html
Use of molecular beacons to verify that the serine hydroxymethyltransferase pseudogene

Background:
          The serine hydroxymethyltransferase processed pseudogene SHMT-ps1 has been suggested to be unique to the order Primates because of the failure to amplify this sequence by PCR from genomic DNAs of any non-primate mammal species. Here, 'molecular beacon' probes specific to SHMT-ps1 were used in an attempt to verify this suggestion.
        
        
          Results:
          In a search for SHMT-ps1-specific sequences using molecular beacons across a range of mammalian species, SHMT-ps1 was only found in primates. The molecular beacon assays also showed that SHMT-ps1 is present in both Old World and New World species but not among prosimians.
        
        
          Conclusions:
          These results suggest that SHMT-ps1 originated close to the origin of the Anthropoidea, some 40 to 50 million years ago.
Child Welfare Worker Safety in the time of COVID:

The Children’s Bureau partnered the CDC to conduct a webinar on Child Welfare Worker Safety in the time of COVID: CDC Recommendations for In-Person Interactions with Families. The purpose of this webinar was to review relevant guidance and recommendations by the Centers for Disease Control and Prevention (CDC) on how to reduce the risk of exposure to COVID-19 while conducting in-person interactions with children and families. Participants also heard how these recommendations are being implemented in practice in Massachusetts.

Browse All COVID-19 Resources

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E40118-T1: [Translated] BENZAZEPINE DERIVATIVES, THEIR PRODUCTION AND USE AS MEDICINAL PRODUCTS.

Compound of general formula I   <IMAGE> (wherein R1 to R6, A, B, E and G are as defined in claim 1) and acid addition salts thereof. The new compounds have valuable pharmacological properties, in particular a heart-rate lowering effect. Processes for preparing the new compounds and pharmaceutical compositions containing them are also described.
Long-term cultivation of colorectal carcinoma cells with anti-cancer drugs induces drug resistance and telomere elongation: an

Background
          The role of telomerase activation in the expression and/or maintenance of drug resistance is not clearly understood. Therefore, we investigated the relationships, among the telomerase activity, telomere length and the expression of multidrug resistance genes in colorectal cancer cell lines cultivated with anti-cancer drugs.
        
        
          Methods
          LoVo and DLD-1 cells were continuously grown in the presence of both CDDP and 5-FU for up to 100 days. Cell proliferation, telomerase activity, telomere length and the expression of multidrug resistance genes were serially monitored as the PDL increased.
        
        
          Results
          The expression of multidrug resistance genes tended to increase as the PDL increased. However, an abnormal aneuploid clone was not detected as far as the cells were monitored by a DNA histogram analysis. Tumor cells showing resistance to anti-cancer drugs revealed a higher cell proliferation rate. The telomere length gradually increased with a progressive PDL. The telomerase activity reached a maximum level at 15 PDL in LoVo cells and at 27 PDL in DLD-1 cells. An increase in the mRNA expression of the telomerase components, especially in hTERT and in hTR, was observed at the same PDLs.
        
        
          Conclusions
          These results suggest that a high telomerase activity and an elongation of telomeres both appear to help maintain and/or increase drug resistance in colorectal cancer cells. Cancer cells with long telomeres and a high proliferative activity may thus be able to better survive exposure to anti-cancer drugs. This is presumably due to an increased chromosome stability and a strong expression of both mdr-1 and MRP genes.
Patent AT-E401470-T1: [Translated] STACKABLE CONSTRUCTION PANEL

A stackable insulating foam panel which has a top side and a bottom side. Each of the panels has a median row of alternating projections and recesses with a similar complementary shape. The median row is disposed between two coplanar edge surfaces. Each projection of the top side is opposed to a recess of the bottom side whereby the top side and/or the bottom side of the panel can be interconnected with either the top side or the bottom side of a like panel. The present invention also concerns a wall form assembly which comprises opposed foam panels disposed in parallel relationship to make a wall form for receiving a flowable material such as concrete and a plurality of connectors for tying the opposed foam panels together.
Compound 525540: 2-(tert-Butyl-dimethyl-silanyloxy)-3-(1-methylpropyl)-quinoxaline

Chemical compound data from PubChem database. IUPAC Name: (3-butan-2-ylquinoxalin-2-yl)oxy-tert-butyl-dimethylsilane. Molecular Formula: C18H28N2OSi. Molecular Weight: 316.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526596: 2,2,4a,9-Tetramethyl-1,2,3,4,4a,5,6,14b-octahydro-picene

Chemical compound data from PubChem database. IUPAC Name: 2,2,4a,9-tetramethyl-1,3,4,5,6,14b-hexahydropicene. Molecular Formula: C26H30. Molecular Weight: 342.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
CCWIS Transition Period and Other Triggers to Change Cost Allocation Plans

This brief DSS presentation provides targeted guidance to title IV-E agencies on whether to submit an updated Cost Allocation Methodology (CAM) or Public Assistance Cost Allocation Plan (PA-CAP) as a result of the Comprehensive Child Welfare Information System (CCWIS) transition period ending on July 31, 2018.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 528020: Benzoic acid, 3,5-dinitro, 2-phenylethyl ester

Chemical compound data from PubChem database. IUPAC Name: 2-phenylethyl 3,5-dinitrobenzoate. Molecular Formula: C15H12N2O6. Molecular Weight: 316.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526689: 2-Isopropyl-4,5-dimethyl-2,5-dihydrothiazole

Chemical compound data from PubChem database. IUPAC Name: 4,5-dimethyl-2-propan-2-yl-2,5-dihydro-1,3-thiazole. Molecular Formula: C8H15NS. Molecular Weight: 157.28. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530264: cis-1,3,5-Cyclohexanetricarboxylic acid, triethyl ester

Chemical compound data from PubChem database. IUPAC Name: triethyl cyclohexane-1,3,5-tricarboxylate. Molecular Formula: C15H24O6. Molecular Weight: 300.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Proteinase-3 as the major autoantigen of c-ANCA is strongly expressed in lung tissue of patients with Wegener's granulomatosis

Proteinase-3 (PR-3) is a neutral serine proteinase present in azurophil granules of human polymorphonuclear leukocytes and serves as the major target antigen of antineutrophil cytoplasmic antibodies with a cytoplasmic staining pattern (c-ANCA) in Wegener's granulomatosis (WG). The WG disease appears as severe vasculitis in different organs (e.g. kidney, nose and lung). Little is known about the expression and distribution of PR-3 in the lung. We found that PR-3 is expressed in normal lung tissue and is upregulated in lung tissue of patients with WG. Interestingly, the parenchymal cells (pneumocytes type I and II) and macrophages, and not the neutrophils, express PR-3 most strongly and may contribute to lung damage in patients with WG via direct interaction with antineutrophil cytoplasmic antobodies (ANCA). These findings suggest that the PR-3 expression in parenchymal cells of lung tissue could be at least one missing link in the etiopathogenesis of pulmonary pathology in ANCA-associated disease.
2013 NSDUH Sampling Error Report

This report compares the estimated (or realized) precisions of a key set of estimates with the targets for the 2013 National Survey on Drug Use and Health (NSDUH), formerly called the National Household Survey on Drug Abuse (NHSDA). The comparison was made with targets specified by the Substance Abuse and Mental Health Services Administration (SAMHSA) and with the predicted precisions that statisticians from RTI International anticipated during the design of the survey. In addition, tables of realized DEFFs are provided. This report is organized as follows. Chapter 2 summarizes the 2013 sample design. Chapter 3 describes the calculation of relative standard errors (RSEs) and DEFFs. Chapter 4 presents tables that compare the observed precisions with the expected precisions. Chapter 5 compares median and mean DEFFs. Chapter 6 presents median and mean DEFFs for specific analysis domains. Finally, concluding remarks are provided in Chapter 7.
MEDLINE/PubMed Baseline Statistics: Min/Max Report

*A file containing all Min/Max Baseline Reports for 2005-2023 in their original format is available in the <b>Attachments</b> section below. A second file includes a separate set of reports, made available from 2002-2017, that did not include OLDMEDLINE records.* 

MEDLINE/PubMed annual statistical reports are based upon the data elements in the baseline versions of MEDLINE®/PubMed are available. For each year covered the reports include: total citations containing each element; total occurrences of each element; minimum/average/maximum occurrences of each element in a record; minimum/average/maximum length of a single element occurrence; average record size; and other statistical data describing the content and size of the elements.
Effect of a short-term in vitro exposure to the marine toxin domoic acid on viability, tumor necrosis factor-alpha, matrix metalloproteinase-9 and superoxide anion release by rat neonatal microglia

Background
          The excitatory amino acid domoic acid, a glutamate and kainic acid analog, is the causative agent of amnesic shellfish poisoning in humans. No studies to our knowledge have investigated the potential contribution to short-term neurotoxicity of the brain microglia, a cell type that constitutes circa 10% of the total glial population in the brain. We tested the hypothesis that a short-term in vitro exposure to domoic acid, might lead to the activation of rat neonatal microglia and the concomitant release of the putative neurotoxic mediators tumor necrosis factor-α (TNF-α), matrix metalloproteinases-2 and-9 (MMP-2 and -9) and superoxide anion (O2-).
        
        
          Results
          In vitro, domoic acid [10 μM-1 mM] was significantly neurotoxic to primary cerebellar granule neurons. Although neonatal rat microglia expressed ionotropic glutamate GluR4 receptors, exposure during 6 hours to domoic acid [10 μM-1 mM] had no significant effect on viability. By four hours, LPS (10 ng/mL) stimulated an increase in TNF-α mRNA and a 2,233 % increase in TNF-α protein In contrast, domoic acid (1 mM) induced a slight rise in TNF-α expression and a 53 % increase (p < 0.01) of immunoreactive TNF-α protein. Furthermore, though less potent than LPS, a 4-hour treatment with domoic acid (1 mM) yielded a 757% (p < 0.01) increase in MMP-9 release, but had no effect on MMP-2. Finally, while PMA (phorbol 12-myristate 13-acetate) stimulated O2- generation was elevated in 6 hour LPS-primed microglia, a similar pretreatment with domoic acid (1 mM) did not prime O2- release.
        
        
          Conclusions
          To our knowledge this is the first experimental evidence that domoic acid, at in vitro concentrations that are toxic to neuronal cells, can trigger a release of statistically significant amounts of TNF-α and MMP-9 by brain microglia. These observations are of considerable pathophysiological significance because domoic acid activates rat microglia several days after in vivo administration.
Venlafaxine hydrochloride

Venlafaxine Hydrochloride is a generic prescription antidepressant that helps balance brain chemicals like serotonin and norepinephrine to treat depression and anxiety. It comes as extended-release oral capsules in 37.5 mg, 75 mg, and 150 mg strengths, manufactured by Zydus Pharmaceuticals USA Inc. (ANDA090174). This information was generated using AI and is provided for informational and research purposes only.
Compound 529728: Methyl 2-chlorobut-2-enoate

Chemical compound data from PubChem database. IUPAC Name: methyl 2-chlorobut-2-enoate. Molecular Formula: C5H7ClO2. Molecular Weight: 134.56. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401334-T1: [Translated] NEW AZACYCLIC ETHYNYL DERIVATIVES

Azacyclic ethynyl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
Compound 529743: 1-Ethylundecyl butyrate

Chemical compound data from PubChem database. IUPAC Name: 3-[(2-methylfuran-3-yl)disulfanyl]butan-2-one. Molecular Formula: C9H12O2S2. Molecular Weight: 216.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526490: {5-Chloro-2-[(cyclopropylmethyl)amino]phenyl}(phenyl)methanone

Chemical compound data from PubChem database. IUPAC Name: [5-chloro-2-(cyclopropylmethylamino)phenyl]-phenylmethanone. Molecular Formula: C17H16ClNO. Molecular Weight: 285.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401144-T1: [Translated] METHOD FOR STRAIGHTENING A METAL STRIP AND STRAIGHTENING MACHINE

The invention relates to a method for straightening a metal strip (1) which is guided in the direction of transportation (R) through a straightening machine (2) and is straightened. In the straightening device (2), the metal strip (1) is impinged upon by a straightening force (F) which is applied by a plurality of straightening rollers (3) in the direction (N) which is perpendicular to the surface of the metal strip (1). According to the invention, prior to the metal strip (1) entering into the straightening machine (2), the thickness (d) of the metal strip (1) is determined and the position (a) of the straightening rollers (3) in the direction (N) which is perpendicular to the surface of the metal strip (1) is taken into account according to the determined thickness (d).